{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, a bioactivity metric, a specific numeric value for that metric, and a unit for that value. The text primarily discusses dosages of various kinase inhibitors in milligrams (mg), but does not provide bioactivity metrics such as IC50, Ki, Kd, EC50, pIC50, pEC50, pKi, or pKd with specific numeric values and units."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nIn embodiments, idelalisib is administered at a dosage of about 100-400 mg (e.g., 100-125, 125-150, 150-175, 175-200, 200-225, 225-250, 250-275, 275-300, 325-350, 350-375, or 375-400 mg), e.g., BID.\nIn embodiments, duvelisib is administered at a dosage of about 15-100 mg (e.g., about 15-25, 25-50, 50-75, or 75-100 mg), e.g., twice a day.\nIn embodiments, rituximab is administered at a dosage of about 350-550 mg/m<sup>2 </sup>(e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m<sup>2</sup>), e.g., intravenously."}
{"final_json": [{"molecule_name": "idelalisib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100-400", "unit": "mg"}, {"molecule_name": "duvelisib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "15-100", "unit": "mg"}, {"molecule_name": "rituximab", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "350-550", "unit": "mg/m^2"}]}
